MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

Hypoparathyroidism Drug Will Move Into Phase III In 2026

 
• By Mandy Jackson
  
HP patients treated with MBX's canvuparatide reduced their daily calcium pill burden (Shutterstock)

More from Clinical Trials

More from R&D